Asset Details
Do you wish to reserve the book?
Frequency of Ceftazidime-Avibactam Susceptibility In Specimens of Carbapenem-Resistant Pseudomonas Aeruginosa In A Tertiary Care Hospital
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Frequency of Ceftazidime-Avibactam Susceptibility In Specimens of Carbapenem-Resistant Pseudomonas Aeruginosa In A Tertiary Care Hospital
Do you wish to request the book?
Frequency of Ceftazidime-Avibactam Susceptibility In Specimens of Carbapenem-Resistant Pseudomonas Aeruginosa In A Tertiary Care Hospital
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Frequency of Ceftazidime-Avibactam Susceptibility In Specimens of Carbapenem-Resistant Pseudomonas Aeruginosa In A Tertiary Care Hospital
2026
Overview
Objective: To determine the frequency of Ceftazidime-Avibactam (CAZ-AVI) susceptibility in specimens of Carbapenem-resistant Pseudomonas aeruginosa (CRPA) at a tertiary care hospital. Study Design: Analytical cross-sectional study. Place and Duration of Study: Department of Microbiology, Combined Military Hospital (CMH), Multan, Pakistan, from Jan-Jun 2024. Methodology: Specimens of carbapenem-resistant Pseudomonas aeruginosa were included in the study to find the susceptibility of CAZ-AVI using the standard Kirby Bauer disc diffusion method. Zones were interpreted using a Vernier caliper following Clinical Standard Institute (CLSI) 2023, where zone of CAZ-AVI ≥21 was considered as susceptible. Results: The total sample size was 103 CRPA specimens, out of which, 47(45.60%) were found to be susceptible to CAZ-AVI with an average zone of inhibition of 16.9 ± 8.8 mm, with male patients showing more susceptibility as compared to females (51.00% vs. 40.40%). The majority 44(68.80%) of resistant cases were from inpatient department as compared to the outpatient department 12(30.80%) (p-value <0.001). Organisms were more susceptible in the specimens bronchioalveolar lavage sputum (87.50% and 75.00% respectively) whereas the most resistant isolates were found in Tracheal aspirate and blood specimens (100.00%) (p-value <0.001). Conclusion: The study demonstrates that approximately 45.60% of carbapenem‑resistant Pseudomonas aeruginosa (CRPA) isolates at a tertiary care hospital are susceptible to Ceftazidime‑Avibactam (CAZ‑AVI), supporting its potential role as a valuable treatment option.
Publisher
Army Medical College Rawalpindi
